Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects

Clinical Therapeutics

Volumn 28, Issue 5, 2006, Pages 734-744

  Ramael, Steven ^a   De Smedt, Florence ^b   Toublanc, Nathalie ^b   Otoul, Christian ^b   Boulanger, Pierre ^b   Riethuisen, Jean Michel ^b   Stockis, Armel ^b  

^a Stuivenberg General Hospital   (Belgium)

^b UCB PHARMA   (Belgium)

Author keywords

antiepileptic drugs; epilepsy; intravenous; levetiracetam; pharmaco kinetics

Indexed keywords

DRUG METABOLITE; ETIRACETAM; NITROGEN; PHOSPHORUS; PLACEBO; UCB L507; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG TOLERABILITY; EUPHORIA; FEMALE; GAS CHROMATOGRAPHY; HUMAN; HYPOTENSION; INJECTION SITE PRURITUS; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSITIONAL DIZZINESS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; TABLET;

ADMINISTRATION, ORAL; ADULT; ALGORITHMS; ANALYSIS OF VARIANCE; ANTICONVULSANTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PIRACETAM; TIME FACTORS;

EID: 33745974941     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.05.004     Document Type: Article

References (24)

1. Fisher R.S., and Ho J. Potential new methods for antiepileptic drug delivery. CNS Drugs 16 (2002) 579-593
2. Cereghino J.J., Mitchell W.G., Murphy J., et al., North American Diastat Study Group. Treating repetitive seizures with a rectal diazepam formulation: A randomized study. Neurology 51 (1998) 1274-1282
3. Fisgin T., Gurer Y., Tezic T., et al. Effects of intranasal midazolam and rectal diazepam on acute convulsions in children: Prospective randomized study. J Child Neural 17 (2002) 123-126
4. Sirven J.I., and Waterhouse E. Management of status epilepticus. Am Fam Physician 68 (2003) 469-476
5. Ben-Menachem E., Falter U., and European Levetiracetam Study Group. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: A multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 41 (2000) 1276-1283
6. Cereghino J.J., Biton V., Abou-Khalil B., et al. Levetiracetam for partial seizures: Results of a double-blind, randomized clinical trial. Neurology 55 (2000) 236-242
7. Shorvon S.D., Lowenthal A., Janz D., et al., European Study Group. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 41 (2000) 1179-1186
8. [published correction appears in Epilepsy Res. 2003:56:209-210]. Morrell M.J., Leppik I., French J., et al. The KEEPER trial: Levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study. Epilepsy Res 54 (2003) 153-161
9. Patsalos P.N. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet 43 (2004) 707-724
10. Editorial. Naeije R., and Torbicki A. More on the noninvasive diagnosis of pulmonary hypertension: Doppler echocardiography revisited. Eur Respir J. 8 (1995) 1445-1449
11. Shah V.P., Midha K.K., Findlay J.W., et al. Bioanalytical method validation-a revisit with a decade of progress. Pharm Res. 17 (2000) 1551-1557
12. Coupez R., Straetemans R., Sehgal G., et al. Levetiracetam: Relative bioavailability and bioequivalence of a 10% oral solution (750 mg) and 750-mg tablets. J Clin Pharmacol 43 (2003) 1370-1376
13. Coupez R., Nicolas J.M., and Browne T.R. Levetiracetam, a new antiepileptic agent: Lack of in vitro and in vivo pharmacokinetic interaction with valproic acid. Epilepsia 44 (2003) 171-178
14. In: Cawello W. (Ed). Parameters for Compartment-Free Pharmacokinetics. Standardisation of Study Design, Data Analysis and Reporting (1999), Shaker Verlag, Aachen, Germany
15. Jones B., and Kenward M.G. Design and Analysis of Goss-over Trials (1989), Chapman and Hall, London, UK
16. Steinijans V.W., and Hauschke D. Update on the statistical analysis of bioequivalence studies. Intj Gar Pharmacol Ther Toxicol 28 (1990) 105-110
17. Chow S.C., and Liu J.P. Design and Analysis of Bioavailability and Bioequivalence Studies. 2nd ed (1998), Marcel Dekker, New York, NY
18. Diletti E., Hauschke D., and Steinijans V.W. Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol 29 (1991) 1-8
19. Perucca E., Gidal B.E., and Baltes E. Effects of antiepileptic comedication on levetiracetam pharmacokinetics: A pooled analysis of data from randomized adjunctive therapy trials. Epilepsy Res. 53 (2003) 47-56
20. Gidal B.E., Baltes E., Otoul C., and Perucca E. Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: A pooled analysis of data from randomized clinical trials. Epilepsy Res. 64 (2005) 1-11
21. Harden C. Safety profile of levetiracetam. Epilepsia 42 Suppl 4 (2001) 36-39
22. Patsalos P.N. Pharmacokinetic profile of levetiracetam: Toward ideal characteristics. Pharmacol Ther. 85 (2000) 77-85
23. Strolin Benedetti M., Whomsley R., Nicolas J.M., et al. Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers. Eur J Clin Pharmacol 59 (2003) 621-630
24. French J., Edrich P., and Cramer J.A. A systematic review of the safety profile of levetiracetam: Anew antiepileptic drug. Epilepsy Res. 47 (2001) 77-90